River Wealth Advisors LLC Purchases 1,148 Shares of Eli Lilly and Company $LLY

River Wealth Advisors LLC boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 11.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,103 shares of the company’s stock after acquiring an additional 1,148 shares during the quarter. Eli Lilly and Company accounts for approximately 1.1% of River Wealth Advisors LLC’s investment portfolio, making the stock its 24th biggest holding. River Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $8,655,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in LLY. Groupe la Francaise increased its position in Eli Lilly and Company by 66.7% during the second quarter. Groupe la Francaise now owns 180,811 shares of the company’s stock worth $141,115,000 after buying an additional 72,332 shares during the last quarter. Arjuna Capital acquired a new stake in shares of Eli Lilly and Company in the second quarter valued at approximately $476,000. Wellspring Financial Advisors LLC boosted its stake in shares of Eli Lilly and Company by 7.3% during the 2nd quarter. Wellspring Financial Advisors LLC now owns 586 shares of the company’s stock worth $457,000 after acquiring an additional 40 shares during the period. Westerkirk Capital Inc. acquired a new position in shares of Eli Lilly and Company during the 2nd quarter worth approximately $9,514,000. Finally, Quantbot Technologies LP acquired a new position in shares of Eli Lilly and Company during the 2nd quarter worth approximately $4,592,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

LLY has been the subject of several research reports. BMO Capital Markets reaffirmed an “outperform” rating and set a $1,100.00 price target on shares of Eli Lilly and Company in a report on Tuesday. Berenberg Bank raised their target price on shares of Eli Lilly and Company from $830.00 to $950.00 and gave the stock a “hold” rating in a research note on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Eli Lilly and Company in a research note on Monday. Deutsche Bank Aktiengesellschaft lowered their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a report on Monday, August 11th. Finally, Leerink Partners upgraded Eli Lilly and Company from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $886.00 to $1,104.00 in a report on Monday, November 10th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,064.57.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $1,045.50 on Wednesday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,111.99. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The firm’s 50-day simple moving average is $901.39 and its 200 day simple moving average is $804.51. The firm has a market cap of $988.39 billion, a price-to-earnings ratio of 68.33, a P/E/G ratio of 1.21 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same quarter in the prior year, the business posted $1.18 EPS. The business’s revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.